ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO467

Case Series of Real-World Use of Percutaneous Arteriovenous Fistulas in an Urban Predominantly Black US Hemodialysis Population

Session Information

  • Dialysis: Vascular Access
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 803 Dialysis: Vascular Access


  • Yadla, Gautam, Emory University, Atlanta, Georgia, United States
  • Niyyar, Vandana Dua, Emory University, Atlanta, Georgia, United States
  • Keyes, Jonathan, Emory University, Atlanta, Georgia, United States
  • Forrester, Nathaniel, Emory University, Atlanta, Georgia, United States
  • Rawls, Forest, Emory University, Atlanta, Georgia, United States
  • Broxton-Key, Rodella, Emory University, Atlanta, Georgia, United States
  • Cobb, Jason, Emory University, Atlanta, Georgia, United States

Arteriovenous fistula (AVF) is the preferred vascular access for end-stage kidney disease (ESKD), but most patients in the US start hemodialysis (HD) with a tunneled dialysis catheter. Percutaneous (pAVF) creation systems (Ellipsys and WavelinQ) allow for non-surgical creation of AVFs. Published pAVF studies so far report higher patency rates (85-96%), less interventions, less surgical complications, and greater patient satisfaction compared to surgically created AVF. The percentage of Black patients varies from 0-20.6% in the literature, which vastly differs from our clinical population. We report a case series of real-world outcomes of pAVF in our urban predominantly Black HD patient population.


Retrospective chart review from 2021-2023 of patients from Emory Dialysis of all patients who received percutaneous AVF.


Eleven patients had pAVF created by four proceduralists using either the Ellipsys or WavelinQ devices. Majority of patients were male (72.7%) and of Black race (91%). Common co-morbidities included hypertension (100%), diabetes mellitus (63.6%), and cardiovascular disease (36.4%). Mean age was 53.6 years, and the mean body mass index (BMI) was 34.6. Dialysis vintage ranged from 0.5 to 9 years, with mean duration of 2.7 years. 91% of patient had a tunneled dialysis catheter before having a fistula. Of 11 patients, 6 (54.5%) had their pAVFs functioning adequately for HD, 4 (36.4%) did not, 1 had 3 angioplasties but her pAVF was not used. Irrespective of ultimate functional patency, all required multiple interventions, with 10 of 11 patients (91%) requiring 2 or more interventions.


Overall, this case series provides real-world data on the use of pAVFs in an urban predominantly Black US dialysis population. To our knowledge, our study has the largest percentage of Black patients in the study population published so far. Our results indicate that though pAVFs can be successfully created in this population, a majority of patients require multiple secondary procedures, and only 54.5% were able to achieve functional patency. Further research with larger sample sizes and longer follow-up is warranted to evaluate the long-term patency rates and complications associated with pAVFs.